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1. Five plus five 
Innogen (the UK ESRC Centre for Social and Economic Research on Innovation in 
Genomics) began its second five-year phase in late 2007. Innogen, a collaboration 
between the University of Edinburgh and the Open University, began in 2002. It 
belongs to the ESRC Genomics Network, made up of two other centres: Cesagen and 
Egenis and the ESRC Genomics Forum. From the beginning, Innogen’s aim has been 
to research the big changes right across the life sciences. We study the new science 
but also the implications for new technologies and how genomics and post-genomics 
might change the life science industries – health, crop and animal. Thus, our aim has 
been to study genomics as an integral part of the life sciences. 
From the beginning, it was our premise that the nasty surprises – and also the big 
prizes – would come from interactions between the three main sets of actors. These 
are: innovators (scientists, technologists, industry); policy makers (including 
government and the emerging new institutions of governance) and public and 
stakeholder groups. Our approach has been to research interactions between all three 
and our ambition is to carry out research with the key actors - innovators, policy 
makers, public and stakeholder groups - not just study them. 
Our initial aims in 2002 were to build an internationally respected centre to enable 
social scientists and the ESRC to take a leading role in (1) policy, (2) public and 
innovation-related debate on life science issues, and to (3) contribute to the shaping of 
the life science trajectory from a well-informed, evidence-based position. Those aims 
remain and, from 2007, we have added that we will “produce theoretically and 
empirically grounded research that advances the knowledge base in social science and 
delivers a sound base for decision-making about life science”, focusing on two 
themes, each comprising two research clusters. The first theme is the evolution of the 
life science economy (with clusters on new life sciences and innovation and on 
globalisation). The second theme concerns the governance of innovation in the life 
sciences (with clusters on governance and regulation; and on conceptualising 
engagement). 
To describe what we have been doing and what we will do in the future, I selectively 
focus on four big questions, one for each research cluster: 
1. “Can big pharma survive new biology?” and, more generally, “Can new 
discoveries in the life sciences transform human health?” 
2. “Can innovation transform global health?” 
3. “Can life science be better regulated?” and: “Can changes in the regulation 
and governance of the life sciences lead to improved human well-being?” 
4. “Can we go beyond ‘talking past each other’?” or, “Can we improve 
governance and engagement?” 
These questions (and others) are being tackled by a large number of Innogen 
researchers and their collaborators around the UK and the World. We have more than 
fifty researchers (academics and doctoral students) and have also been able to build 
very important relations with colleagues in many institutions. One key partner at the 
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University of Edinburgh is the AHRC Script Centre (which edits this journal) with 
whom we have a range of joint activities. 
2. Question 1: Can big pharma survive new biology? 
On the first question the big pharmaceutical firms do seem, so far, to be surviving 
new biology. The long-term sectoral dominance of multi-national pharmaceutical 
companies has been remarkable – the regulation-driven drug discovery pipeline 
system has endured for half a century, dominated by a few big pharma firms. But the 
pharmaceutical industry is certainly maturing and it has been getting harder and 
harder to find new blockbuster drugs. Research and Development (R&D) spending 
has been rising, but there has been no corresponding increase in the number of drug 
launches. Our results show that, so far, new biology is beginning to change the 
industry. But rather than biotechnology start-ups ending the dominance of the big 
pharmaceutical firms, they have acted to prop the system up. 
Small biotech companies, with very few early exceptions, have been unable to break 
the regulatory hurdle of clinical trials and the massive expense of entry. But they do 
have knowledge – even if they cannot develop products. Pharmaceutical firms have 
begun to take advantage of this new knowledge with a range of new corporate 
strategies. For example, big pharma has moved to outsource R&D to small biotech 
companies. One example of this is the big increase in R&D strategic partnerships. Big 
pharma has also accelerated its buying-up of biotech start-ups. 
At the same time, we have seen the rise of translational medicine and attempts to 
build new institutions that link innovation systems to health systems. Innogen 
provides research-based modules on innovation, risk regulation and governance for 
the world’s first distance education course in translational medicine at Edinburgh. 
But, so far, we have seen no big social revolution from new genetic, genomic and 
post-genomic biology. 
But our research suggests possible disruptive change in future. We are seeing systems 
level turbulence – turbulence at many levels – that may make it difficult to control. 
Briefly: 
• Control of the science is changing: not just big pharma, but wide ranging 
groups of firms, institutes, universities, medical units and partnerships; 
• Increased demand for drugs from developing countries and neglected diseases: 
linked to calls for radical changes in innovation dynamics – calls linked 
importantly to new money from Gates et al; 
• Continued lack of trust in the drug industry; and 
• Drugs for small populations, rather than blockbusters.  
These changes could lead to changes in the regulatory system and this, in turn, could 
trigger changes throughout the whole system. 
Innogen will be studying these big changes in the coming years. Figure 1 summarises 
some of our projects. These are focused on science dynamics, technology dynamics 
and industrial dynamics. 
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 Examples of projects 
Science dynamics Emergence of systems biology and 
synthetic biology 
Technology dynamics Translational medicine research 
collaboration 
Industry/innovation dynamics Erosion of big pharma; drivers of biotech 
firm innovative performance; regional 
dynamics and internationalisation 
Figure 1: New life sciences and innovation – some projects 
3. Question 2: Can innovation transform global health? 
The second question concerns genomics and global health. Here we focus on two 
issues: “catch-up” and global health and agricultural innovation partnerships. We 
have comprehensive results on the catch-up of industrially developing countries, like 
China, India, Brazil and Argentina, as well as on smaller countries in Africa and Asia. 
Some countries like Argentina, India, Brazil and China, are rapidly increasing 
capabilities, albeit from a low base. For example, there is a significant globalisation of 
clinical trial sites in Eastern Europe, Latin America and Asia. Obviously, low cost is 
one of several factors which accounts for this, but our results show growth in 
capabilities in the global south. The use of the clinical trials example (rather than, say, 
patent data), is to focus not just on the science but also on how new institutional 
systems for global health innovation and product development go beyond science and 
its application. 
The Innogen team around Joanna Chataway is the first to research global health 
public-private partnerships (PPPs) as systems of global governance that integrate 
health systems with innovation systems. Until now, these themes have been weakly 
connected. New institutions, like the International Aids Vaccine Initiative (IAVI), 
have been established in an attempt to deal with this gap. Figure 2 summarises some 
of our ongoing projects in this research cluster. 
Our studies highlight the importance of partnerships for integrating international 
science-based initiatives with local realities, local involvement and learning. We 
found that the IAVI has made a contribution to capacity building in genomics and 
associated areas in many developing countries. For example, Rwanda, Kenya and 
Uganda have developed centres for vaccine clinical trials. The IAVI is, we argue, a 
potential nexus of innovation, advocacy and health development. 
Overall, then, our answer to the second question is that new governance systems for 
global disease innovation are indeed beginning to change the global health 
environment. We may be witnessing a realignment of clinical practice, lab research 
and biomedical application and a change from a drug pipeline innovation system to a 
broader health-based system. 
 
Global health technology networks (access, inclusion) 
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Global health public-private partnerships as systems of global governance 
Institutional transformation of the international agricultural system 
Innovation in pharma and equity in health 
Figure 2: “Can innovation transform global health?” – some projects 
4. Question 3: Can life science be better regulated? 
The simple third question entails further complex and serious questions such as “how 
can policy and regulatory systems keep pace with rapidly evolving developments like 
stem cells, genetic databases and synthetic biology?” On the one hand, there are  
increasingly requirements and public pressure for strong government and good 
evidence-bases for policy decisions. On the other, there are demands for a greater 
degree of stakeholder engagement. Is this leading to complexities that cannot be 
resolved? In this area of increasing complexity, can society tailor the necessary public 
governance of innovative technology (and its risks) whilst fostering innovation? 
Our initial research on these topics, begun twenty years ago, focused on decision-
making concerning agricultural pesticides and genetically-modified (GM) crops and 
on the emergence of precautionary regulation. At Innogen, we have broadened our 
foci to look now at the relationship between regulation and governance. Cathie Lyall 
and colleagues are presently co-editing a book Limits to Governance in the Life 
Sciences, which will offer a constructive critique of the new governance agenda for 
science and technology from a range of perspectives. 
Figure 3 gives other examples of our current research. We have very productive links 
with the AHRC Script centre including research on intellectual property and public 
goods, and on law-making practices in developing countries. Some countries are 
adopting regulation of life sciences, including Argentina. We are collaborating with 
Argentinian research colleagues, regulators and policy makers to study the 
construction of new regulatory frameworks. More generally, we are expanding our 
research into risk regulation in the life sciences. 
 
Multi-level governance and its limitations 
Assessing democratic governance 
Governing identity transformation 
Law making practices for new life sciences 
Intellectual property and public interest 
Towards ‘smart’ regulation 
Figure 3: Governance and regulation – some projects 
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5. Question 4: Can we get beyond talking past each other? 
Our fourth question concerns engagement with genomics. On this question, we have 
tried to look for novel ways of getting beyond ‘talking past each other’, with research 
on: stem cell donation; families and genetic databases and reconciling patient rights 
and the public interest (see Figure 4). We work with Generation Scotland and are part 
of the successful £1.2m bid for a Beacon of Public Engagement Beltane. 
Our research on UK farmers’ experiences of GM crops fills a gap since, surprisingly, 
farmers have been relatively ignored in the GM crop debate. Farmers are critical that 
they were not consulted on the design of the GM trials and how outcomes were to be 
reported. They felt that their experience and skills were not called on in the debates. 
Thus, even a relatively well-supported engagement initiative, on an issue which was 
previously a disaster for engagement, was not seen as useful by all stakeholders. 
More generally, the research of Robin Williams has suggested we need to step back 
and take a critical look at the outcomes of engagement activities. Attempts to govern 
and regulate science and technology in the very early stages of its shaping may not 
succeed in facilitating better outcomes, given the unpredictability of innovation 
pathways. It may even be counter-productive by closing down options too early. 
So our research on engagement has aimed to understand these complexities in order to 
improve future engagement, to get beyond ‘talking past each other’. This is a major 
theme for our next five years as we continue on our journey. 
 
Generation Scotland (biobanks and public consultation) 
Social dynamics of public engagement in stem cells 
Patient expertise and engagement 
Values and interests in stakeholder engagement 
Figure 4: Conceptualising Engagement 
 
To summarise, our research has shown that the increasing strains in health innovation 
cannot be analysed just by studying the science. Social research on how biology is 
changing drug innovation systems, health markets and policies, and, particularly, 
governance and regulatory institutions is needed. 
 
